TLP
HBIO icon

Tri Locum Partners’s Harvard Bioscience HBIO Stock Holding History

Tri Locum Partners’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,003
Closed -$28K – 63
2022
Q4 		$28K Buy
+1,003
New +$24.7K 0.01% 63

Other funds holding HBIO

2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Tri Locum Partners's HBIO Position: Q1 2023 in Review

Tri Locum Partners sold out of Harvard Bioscience (HBIO) in Q1 2023, closing a stake of 1,003 shares — an estimated $28K sold.

Tri Locum Partners first reported a position in HBIO in Q4 2022 and held it in 1 quarter. The position peaked at $28K in Q4 2022. 65 funds tracked by Wall St. Rank hold HBIO as of Q1 2023.

  • Tri Locum Partners reported no remaining Harvard Bioscience position as of Q1 2023 after selling out during the quarter.
  • Tri Locum Partners sold 1,003 Harvard Bioscience shares in Q1 2023, an estimated $28K.
  • Tri Locum Partners first reported a position in Harvard Bioscience in Q4 2022 and held it in 1 quarter.
  • Tri Locum Partners's Harvard Bioscience position peaked at $28K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2023.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.